C4 Therapeutics (CCCC) Receivables (2019 - 2025)
Historic Receivables for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $6.5 million.
- C4 Therapeutics' Receivables fell 3673.73% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 3673.73%. This contributed to the annual value of $3.1 million for FY2024, which is 7370.96% down from last year.
- Latest data reveals that C4 Therapeutics reported Receivables of $6.5 million as of Q3 2025, which was down 3673.73% from $2.2 million recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Receivables peaked at $13.6 million during Q1 2024, and registered a low of $500000.0 during Q3 2023.
- Its 5-year average for Receivables is $4.5 million, with a median of $3.1 million in 2024.
- Its Receivables has fluctuated over the past 5 years, first crashed by 7423.02% in 2022, then skyrocketed by 247556.82% in 2024.
- Over the past 5 years, C4 Therapeutics' Receivables (Quarter) stood at $5.7 million in 2021, then plummeted by 74.23% to $1.5 million in 2022, then soared by 701.02% to $11.8 million in 2023, then crashed by 73.71% to $3.1 million in 2024, then skyrocketed by 110.9% to $6.5 million in 2025.
- Its Receivables was $6.5 million in Q3 2025, compared to $2.2 million in Q2 2025 and $8.0 million in Q1 2025.